1995 Cumulative Table of Contents
Vol. 31, No. 1—1995

1994 Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU)—Workshops and Symposia

1 Editor's Note—Matthew V. Rudorfer

3 A Brief History of the New Clinical Drug Evaluation Unit (NCDEU) Meeting– How It Began— Robert F. Prien

From Scientific Knowledge to the Clinic

7 From Scientific Knowledge to the Clinical Practice of Psychopharmacology: Can the Gap Be Bridged?—A. John Rush and Robert F. Prien

Antidepressants: Can We Determine How Quickly They Work?

21 Foreword–Samuel Gershon

23 Antidepressants: Can We Determine How Quickly They Work? Issues From the Literature—Albert T. Derivan

29 Characterizing Onset in Psychopharmacological Clinical Trials—Eugene M. Laska and Carole Siegel

37 Speed of Onset—Paul Leber

41 Are 2-Week Trials Sufficient to Indicate Efficacy?—Stuart A. Montgomery

45 Justifying a "Fast Acting" Claim for Antidepressant Drugs—John E. Overall

Pharmacoeconomics Research Applied to Psychopharmacology Development and Evaluation

57 Methods of Pharmacoeconomic Evaluation of New Medical Treatments in Psychiatry—Dennis A. Revicki and Bryan R. Luce

67 Re-Engineering Drug Development: Integrating Pharmacoeconomic Research Into the Drug Development Process—J.L. Data, R.J. Willke, J.R. Barnes, and P.J. DiRoma

Developing Clinical Trials in Children and Adolescents

75 Developmental Perspectives in Pediatric Psychopharmacology—Benedetto Vitiello and Peter S. Jensen

New Developments in Psychosocial, Pharmacological, and Combined Treatments of Conduct Disorders in Aggressive Children

83 Parent-Child Interaction Therapy: A Psychosocial Model for the Treatment of Young Children With Conduct Problem Behavior and Their Families—Sheila M. Eyberg, Stephen R. Boggs, and James Algina

93 An Update on the Use of Lithium Carbonate in Aggressive Children and Adolescents With Conduct Disorder—Magda Campbell, Vivian Kafantaris, and Jeanette E. Cueva

Who Enters Therapeutic Trials?

103 Illness Characteristics of Patients in Clinical Drug Studies of Mania—Charles L. Bowden, Joseph R. Calabrese, Bruce A. Wallin, Alan C. Swann, Susan L. McElroy, S. Craig Risch, and Robert M.A. Hirschfeld

111 A Comparison of Demographic Variables, Symptom Profiles, and Measurements of Functioning in Symptomatic Volunteers and an Outpatient Clinical Population—Mark Hyman Rapaport, Theresa Frevert, Shirley Babior, Sidney Zisook, and Lewis L. Judd

Long-Term Treatment of Anxiety Disorders

115 Maintenance Treatment Studies in Anxiety Disorders: Some Methodological Notes—Karl Rickels and Edward Schweizer

Advances in the Epidemiology and Therapy of Social Phobia: Directions for the Nineties

125 A Review of Social Phobia—Mark Hyman Rapaport, Gregory Paniccia, and Lewis L. Judd

Medicinal Plants and Dietary Supplements: Sources for Innovative Treatments or Adjuncts?

131 Introduction—Jerry Cott

139 Pharmacologic Profile of Natural Products Used to Treat Psychotic Illnesses—In-Won Chung, Yong-Sik Kim, Jong-Seog Ahn, Hyun-Sun Lee, Guang Chen, Husseini K. Manji, William Z. Potter, and David Pickar

147 Natural Substances in Psychiatry (*Ginkgo biloba* in Dementia)—Turan Itil and David Martorano

159 Free Radical Involvement in Neuropsychiatric Illnesses—James B. Lohr and John A. Browning

167 Inositol Treatment in Psychiatry—Jonathan Benjamin, Galila Agam, Joseph Levine, Yuly Bersudsky, Ora Kofman, and R.H. Belmaker

177 Commentary—Novel Psychotherapeutic Drugs: A Role for Ethnobotany—James A. Duke

NIMH/MacArthur Foundation Workshop Report

185 Treatment of Depression in Late Life—Barry D. Lebowitz, Rick A. Martinez, George Niederehe, Jane L. Pearson, Charles F. Reynolds III, Matthew V. Rudorfer, Lon S. Schneider, and David J. Kupfer

Vol. 31, No. 2—1995

1994 NCDEU (New Clinical Drug Evaluation Unit) Annual Meeting—Posters and Free Communications

203 Editor's Note—Matthew V. Rudorfer

Mood Disorders

205 Treatment of Chronic Depression With Sertraline or Imipramine: Preliminary Blinded Response Rates and High Rates of Undertreatment in the Community—Martin B. Keller, Wilma Harrison, Jan A. Fawcett, Alan Gelenberg, Robert M.A. Hirschfeld, Daniel Klein, James Kocsis, James P. McCullough, A. John Rush, Alan Schatzberg, and Michael E. Thase

213 Stability of Remission During Tricyclic Antidepressant Continuation Therapy for Dysthymia—James H. Kocsis, Richard A. Friedman, John C. Markowitz, Nina Miller, Leah Gniwesch, and Judith Bram

217 Comparative Neurotransmitter Reuptake and Anticholinergic Potencies of the 8-Hydroxy Metabolites of Clomipramine—Ricardo Núñez and James M. Perel

223 Patterns of Improvement in Depressive Symptoms With Fluoxetine Treatment—John Worthington, Maurizio Fava, Katharine Davidson, Jonathan Alpert, Andrew A. Nierenberg, and Jerrold F. Rosenbaum

227 The Effects of Fluoxetine on Symptoms of Insomnia in Depressed Patients—Winston G. Satterlee and Douglas Faries

239 Onset of Menses in Two Adult Patients With Prader-Willi Syndrome Treated With Fluoxetine—Julia K. Warnock, Anita H. Clayton, Howard A. Shaw, and Teri O'Donnell

243 Amplitude/Intensity Functions of Auditory Event-Related Potentials Predict Responsiveness to Bupropion in Major Depressive Disorder—Stephen R. Paige, Shelton E. Hendricks, Denis F. Fitzpatrick, Scott Balogh, and William J. Burke

249 The Use of Decision Analysis in the Pharmacoeconomic Evaluation of an Antidepressant: A Cost-Effectiveness Study of Nefazodone—Susan F. Anton and Dennis A. Revicki

259 Antidepressant-Induced Tardive Dyskinesia: Review and Case Report—Anita H. Clayton

265 Lithium Combined With Carbamazepine or Haloperidol in the Treatment of Mania—Joyce G. Small, Marietta H. Klapper, Jon D. Marhenke, Victor Milstein, Gregory C. Woodham, and Jeffrey J. Kellams

Anxiety Disorders

273 Pattern of Placebo Response in Panic Disorder—M. Katherine Shear, Andrew C. Leon, Mark H. Pollack, Jerrold F. Rosenbaum, and Martin B. Keller

279 Skin Picking as a Symptom of Body Dysmorphic Disorder—Katharine A. Phillips and Sarah L. Taub

289 International Study of Expert Judgment on Therapeutic Use of Benzodiazepines and Other Psychotherapeutic Medications: III. Clinical Features Affecting Experts' Therapeutic Recommendations in Anxiety Disorders—E.H. Uhlenhuth, Mitchell B. Balter, Thomas A. Ban, and Kenneth Yang

Alcohol Dependence

297 Preliminary Report: Double-Blind, Placebo-Controlled Study of Fluoxetine in Depressed Alcoholics—Jack R. Cornelius, Ihsan M. Salloum, Marie D. Cornelius, James M. Perel, Joan G. Ehler, Patricia J. Jarrett, Robert L. Levin, Ann Black, and J. John Mann

305 The Utility of Diazepam Loading in the Treatment of Alcohol Withdrawal Among Psychiatric Inpatients—Ihsan M. Salloum, Jack R. Cornelius, Dennis C. Daley, and Michael E. Thase

Schizophrenia

311 Do White-Cell Count Spikes Predict Agranulocytosis in Clozapine Recipients?—Jose Ma. J. Alvir, Jeffrey A. Lieberman, and Allan Z. Safferman

315 A Comparison of European and American Dosing Regimens of Schizophrenic Patients on Clozapine: Efficacy and Side Effects—Simcha Pollack, Jeffrey A. Lieberman, W. Wolfgang Fleischhacker, Michael Borenstein, Allan F. Safferman, Martina Hummer, and Martin Kurz

321 Clinical and Acoustic Measures of the Negative Syndrome—Murray Alpert, Enrique R. Pouget, Cecile Sison, Mohamed Yahia, and Edward Allan

Dementia

327 Prospective Cytochrome P450 Phenotyping for Neuroleptic Treatment in Dementia—Bruce G. Pollock, Benoit H. Mulsant, Robert A. Sweet, Jules Rosen, Linda P. Altieri, and James M. Perel

333 Neuroleptic Treatment of Elderly Patients—Margaret G. Woerner, Jose Ma. J. Alvir, John M. Kane, Bruce L. Saltz, Jeffrey A. Lieberman

Disorders of Childhood and Adolescence

339 Lymphocyte Glucocorticoid Receptor: Predictor of Sertraline Response in Adolescent Major Depressive Disorder (MDD)—Floyd R. Sallee, Lori Nesbitt, Douglas Dougherty, Raouf Hilal, V.S. Nandagopal, and Gopalan Sethuraman

347 The Comorbidity of Attention-Deficit Hyperactivity Disorder in Adolescent Mania: Potential Diagnostic and Treatment Implications—Scott A. West, Stephen M. Strakowski, Kenji W. Sax, Kelly L. Minnery, Susan L. McElroy, and Paul E. Keck, Jr.

353 Methylphenidate Effects on a Laboratory Aggression Measure in Children With ADHD—Charles D. Casat, Deborah A. Pearson, Mary Jo Van Davelaar, and Don R. Cherek

357 Neuropsychological Effects of Amphetamine May Correlate With Personality Characteristics—Kirsten Fleming, Llewellyn B. Bigelow, Daniel R. Weinberger, and Terry E. Goldberg

363 Haloperidol-Related Dyskinesias and Pre- and Perinatal Complications in Autistic Children—Jorge L. Armenteros, Phillip B. Adams, Magda Campbell, and Zena W. Eisenberg

371 A Comparison of Live and Videotape Ratings: Clomipramine and Haloperidol in Autism—Laura E. Sanchez, Phillip B. Adams, Suzan Uysal, Alejandra Hallin, Magda Campbell, and Arthur M. Small

379 The Lithium Test Dose Prediction Method in Aggressive Children—Richard P. Malone, Mary Anne Delaney, James F. Luebbert, Mary A. White, Krista A. Biesecker, and Thomas B. Cooper

383 Schizophrenia in Hospitalized Adolescents: Clinical Diagnosis, *DSM-III-R, DSM-IV,* and *ICD-10* Criteria—Jorge L. Armenteros, Bryan W. Fennelly, Alejandra Hallin, Phillip B. Adams, Paul Pomerantz, Monica Michell, Laura E. Sanchez, and Magda Campbell

Assessment and Rating Instruments

389 Comparative Analysis of Three PMS Assessment Instruments—The Identification of Premenstrual Syndrome With Core Symptoms—Susan Thys-Jacobs, Jose Ma. J. Alvir, and Peter Fratarcangelo

397 Assessment of Paroxetine-Induced Sexual Dysfunction Using the Changes in Sexual Functioning Questionnaire—Anita H. Clayton, Justine E. Owens, and Elizabeth L. McGarvey

415 The SDDS-PC™: A Diagnostic Aid For Multiple Mental Disorders in Primary Care—Mark Olfson, Andrew C. Leon, W. Eugene Broadhead, Myrna M. Weissman, James E. Barrett, Robert S. Blacklow, Thomas T. Gilbert, and Edmund S. Higgins

421 Cues to the Assessment of Affects and Moods: Speech Fluency and Pausing—Murray Alpert, Enrique R. Pouget, and Raul Silva

425 Psychometric Characteristics of the Wender Utah Rating Scale (WURS): Reliability and Factor Structure for Men and Women—Mark A. Stein, Ron Sandoval, Emily Szumowski, Nancy Roizen, Mark A. Reinecke, Thomas A. Blondis, and Zanvel Klein

Data Interpretation

435 Pitfalls in Presenting and Interpreting Clinical Trial Data—Ole J. Thienhaus

439 Venlafaxine: Measuring the Onset of Antidepressant Action—Albert Derivan, A. Richard Entsuah, and Dianne Kikta

Basic Science Topics For the Clinical Investigator

449 Down-Regulation of PKC α by Lithium *In Vitro*—Jose A. Bitran, Husseini K. Manji, William Z. Potter, and Fabian Gusovsky

Vol. 31, No. 3—1995

453 Editor's Note—Matthew V. Rudorfer

International Psychopharmacology Algorithm Project Report

457 Introduction—Kenneth O. Jobson and William Z. Potter

461 A. Algorithms for the Treatment of Schizophrenia—Carlos A. Zarate, Jr., David G. Daniel, Bruce J. Kinon, Robert E. Litman, Dieter Naber, David Pickar, and Mitsumoto Sato

469 B. Algorithms for the Treatment of Bipolar, Manic-Depressive Illness—Trisha Suppes, Joseph R. Calabrese, Philip B. Mitchell, Peggy J. Pazzaglia, William Z. Potter, Matthew V. Rudorfer, and Deborah A. Zarin

475 C. Algorithms for the Treatment of Subtypes of Unipolar Major Depression—J. Craig Nelson, John P. Docherty, Gary M. Henschen, Siegfried Kasper, Andrew A. Nierenberg, and Nicholas G. Ward

483 D. Algorithm for the Treatment of Panic Disorder With Agoraphobia—Kenneth O. Jobson, Jonathan R.T. Davidson, R. Bruce Lydiard, Una D. McCann, Mark H. Pollack, and Jerrold F. Rosenbaum

487 E. Algorithm for the Treatment of Obsessive-Compulsive Disorder (OCD)—James W. Jefferson, Margaret Altemus, Michael A. Jenike, Teresa A. Pigott, Dan J. Stein, and John H. Greist

491 References for the International Psychopharmacology Algorithm Project Report

501 Appendix I - An Algorithm for Schizophrenia in Japan—Mitsumoto Sato

505 Appendix II - International Psychopharmacology Algorithm Project Participants

Novel Antidepressants Report

509 Novel French Antidepressants Not Available in the United States—Philip B. Mitchell

Abstracts from the 1995 New Clinical Drug Evaluation Unit (NCDEU) Meeting

521 Free Communications

541 Poster Session

Vol. 31, No. 4—1995

1995 NCDEU Workshops and Symposia

637 Editor's Note—*Matthew V. Rudorfer*

Geriatric Psychopharmacology

641 Instrumental Measures in Geriatric Psychopharmacology—*Barry D. Lebowitz, Bruce G. Pollock, Michael P. Caligiuri, Alan Kluger, and Fouzia Laghrissi-Thode*

651 Prolactin Response to Neuroleptic Challenge in Late-Life Psychosis—*Robert A. Sweet, Bruce G. Pollock, Benoit H. Mulsant, Jules Rosen, and Ruth A. Henteleff*

659 Double-Blind Comparison of Paroxetine and Nortriptyline on the Postural Stability of Late-Life Depressed Patients—*Fouzia Laghrissi-Thode, Bruce G. Pollock, Mark C. Miller, Benoit H. Mulsant, Linda Altieri, and Mitchell S. Finkel*

NIDA - NIAAA Workshop: Efficacy of Therapies in Drug and Alcohol Addiction

665 Strategies for Treatment of Alcohol Problems—*John P. Allen, Raye Z. Litten, and Joanne B. Fertig*

671 Quantitative Versus Qualitative Urinalysis for Benzoylecgonine in Clinical Trials for the Assessment of Cocaine Use—*Shou-Hua Li, C. Nora Chiang, Betty C. Tai, Charles K. Marschke, and Richard L. Hawks*

681 Medications Development for Alcohol Use Disorders—*Curtis Wright*

Gender Differences in Risk Factors for Mood and Anxiety Disorders: Implications for Clinical Treatment Research

687 Introduction—*Mary C. Blehar*

693 Light Therapy in Patients With Rapid Cycling Bipolar Disorder: Preliminary Results—*Ellen Leibenluft, Erick H. Turner, Susana Feldman-Naim, Paul J. Schwartz, Thomas A. Wehr, and Norman E. Rosenthal*

699 Anxiety Disorders in Pregnant and Postpartum Women—*M. Katherine Shear and Oommen Mammen*

711 Gender Differences in Presentation of Chronic Major Depression—*Susan G. Kornstein, Alan F. Schatzberg, Kimberly A. Yonkers, Michael E. Thase, Gabor I. Keitner, Christine E. Ryan, and David Schlager*

Pharmacoeconomics Made Simple

719 Risperidone Use in a Teaching Hospital During Its First Year After Market Approval: Economic and Clinical Implications—*Cameron S. Carter, Benoit H. Mulsant, Robert A. Sweet, RaeAnne Maxwell, Kim Coley, Rohan Ganguli, and Robert Branch*

727 The Importance of Considering Non-Monetary Costs and Benefits in Selecting Pharmacologic Interventions in Mental Health—*Andreas M. Pleil*

735 Pharmaceutical Decisionmaking: Pharmacoepidemiology or Pharmacoeconomics—Who's in the Driver's Seat?—*Julie Magno Zito and George Provenzano*

NCDEU Update

745 Natural Product Formulations Available in Europe for Psychotropic Indications—*Jerry Cott*

Reports on Venlafaxine

753 Venlafaxine in Depressed Geriatric Outpatients: An Open-Label Clinical Study—*Arifulla Khan, Richard Rudolph, Barry Baumel, James Ferguson, Patrick Ryan, and Ram Shrivastava*

759 Effectiveness of Venlafaxine Treatment in a Broad Spectrum of Depressed Patients: A Meta-Analysis—*A. Richard Entsuah, Richard L. Rudolph, and Rohini Chitra*

767 Venlafaxine in Social Phobia—*Jeffrey E. Kelsey*

773 Venlafaxine in the Treatment of Borderline Personality Disorder—*Paul J. Markovitz and Susan C. Wagner*

779 An Open Trial of Venlafaxine in Adult Patients With Attention Deficit Hyperactivity Disorder—*Dawson Hedges, Frederick W. Reimherr, Anissa Rogers, Robert Strong, and Paul H. Wender*

785 Open-Label Trial of Venlafaxine in Adults With Attention Deficit Disorder—*Lenard A. Adler, Sandra Resnick, Michael Kunz, and Orrin Devinsky*

Psychiatric Pharmacy Research Workshop: The Promise and Pitfalls of Polypharmacotherapy in the Nineties

789 Issues in Polypharmacotherapy: Focus on Depression in Schizophrenia—*Robert L. Dufresne*

1995 Cumulative Table of Contents

1995 Cumulative Author Index

1995 Cumulative Keyword Index